Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777133 | 0.81 | MAPT (0.58) | MAPTRAB9AL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL29052849 | 0.79 | CTSB (0.41) | CTSBMAPTRAB9AL3MBTL1LMNA | |
| SCHEMBL20571804 | 0.77 | CTSB (0.51) | CTSBMAPTRAB9ALMNAALDH1A1 | |
| SCHEMBL4892950 | 0.73 | MAPT (0.42) | MAPTRAB9ALMNAALDH1A1NPC1 | |
| SCHEMBL4768490 | 0.71 | MAOA (0.39) | MAPTRAB9AL3MBTL1LMNAALDH1A1 | |
| SCHEMBL29052812 | 0.71 | ALDH1A1 (0.42) | CTSBMAPTLMNATP53ALDH1A1 | |
| SCHEMBL29480782 | 0.71 | ALDH1A1 (0.42) | CTSBMAPTLMNATP53ALDH1A1 | |
| SCHEMBL29052811 | 0.71 | ALDH1A1 (0.42) | CTSBMAPTLMNATP53ALDH1A1 | |
| SCHEMBL7219657 | 0.69 | CTSB (0.55) | CTSBMAPTALDH1A1 | |
| SCHEMBL16059880 | 0.68 | MEN1 (0.48) | CTSBMAPTL3MBTL1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1945304-A2 | IMIDAZO-PYRIDINE CONTAINING BETA AGONISTS, METHOD FOR PRODUCING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007048843-A2 | IMIDAZO-PYRIDINE CONTAINING BETA AGONISTS, METHOD FOR PRODUCING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007048843-A2 | IMIDAZO-PYRIDINE CONTAINING BETA AGONISTS, METHOD FOR PRODUCING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | ADRB3, ADRB2, ADRB1 | CTSB 3007/4885MAPT 4073/4885RAB9A 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.